Blood for Immune Response to Provenge® in HRPC
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
This study is being conducted to assess and monitor immune response in patients with minimally symptomatic or asymptomatic hormone refractory prostate cancer who will be receiving Provenge® (Sipuleucel-T) therapy as part of their standard of care treatment regimen. The trial only involves the collection of additional blood samples for the purposes of monitoring immune response. These samples will be taken at 7 time points before, during and after patients receive Provenge® (Sipuleucel-T). There will be no other study-specific procedures performed (other than the blood draws) nor any use of investigational agents in this study.
Condition |
---|
Prostate Cancer Immune Response to Provenge |
Study Type: | Observational |
Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
Official Title: | Blood Samples to Evaluate Immune Response to Provenge® (Sipuleucel-T) inHormone Refractory Metastatic Prostate Cancer Patients |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Subjects that will be included in this study will be receiving Provenge as standard of care treatment for their prostate cancer and will be willing to consent to the additional blood draws.
In order for patients to receive treatment with Provenge® (Sipuleucel-T) at the Mary Crowley clinic, patients must consent to the additional blood draws and be willing to come into the clinic in adherence to the schedule of blood sample collections. Patients who do not consent to these immune response blood samples will be unable to receive Provenge® (Sipuleucel-T) at Mary Crowley but will be referred to a another physician and/or clinic able to provide Provenge® (Sipuleucel-T).
No publications provided
Responsible Party: | John Nemunaitis, MD, Executive Medical Director, Mary Crowley Medical Research Center |
ClinicalTrials.gov Identifier: | NCT01274572 History of Changes |
Other Study ID Numbers: | MC 10-11 |
Study First Received: | January 10, 2011 |
Last Updated: | June 21, 2011 |
Health Authority: | United States: Mary Crowley Medical Research Center IRB |
Additional relevant MeSH terms:
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site |
Neoplasms Genital Diseases, Male Prostatic Diseases |
ClinicalTrials.gov processed this record on October 18, 2012